Author:
Wei Jia,Liu Ronghua,Liu Rong,Xiang Tao
Publisher
Springer Nature Singapore
Reference41 articles.
1. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12:2333–44.
2. Cioffi R, Bergamini A, Gadducci A, et al. Reproductive outcomes after gestational trophoblastic neoplasia. A comparison between single-agent and multiagent chemotherapy: retrospective analysis from the MITO-9 group. Int J Gynecol Cancer. 2018;28:332–7.
3. Zhou WB, Yin H, Liu XA, et al. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. BMC Cancer. 2010;10:281.
4. Long JP, Wan F, Zhang F, et al. DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer. Eur Rev Med Pharmacol Sci. 2016;20:1087–92.
5. Anderson RA, Remedios R, Kirkwood AA, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018;19:1328–37.